Cargando…
The Plk1 Inhibitor BI 2536 Temporarily Arrests Primary Cardiac Fibroblasts in Mitosis and Generates Aneuploidy In Vitro
BI 2536 is a new anti-mitotic drug that targets polo-like kinase 1 (Plk1) and is currently under clinical development for cancer therapy. The effect of this drug on cancer cells has been extensively investigated, but information about the effects on primary dividing cells and differentiated non-divi...
Autores principales: | Lu, Bo, Mahmud, Hasan, Maass, Alexander H., Yu, Bo, van Gilst, Wiek H., de Boer, Rudolf A., Silljé, Herman H. W. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945759/ https://www.ncbi.nlm.nih.gov/pubmed/20886032 http://dx.doi.org/10.1371/journal.pone.0012963 |
Ejemplares similares
-
Regulation of the (pro)renin–renin receptor in cardiac remodelling
por: Mahmud, Hasan, et al.
Publicado: (2012) -
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
por: Yin, Meimei, et al.
Publicado: (2011) -
AKIP1, a Cardiac Hypertrophy Induced Protein that Stimulates Cardiomyocyte Growth via the Akt Pathway
por: Yu, Hongjuan, et al.
Publicado: (2013) -
The dual role of BI 2536, a small-molecule inhibitor that targets PLK1, in induction of apoptosis and attenuation of autophagy in neuroblastoma cells
por: Li, Zhiheng, et al.
Publicado: (2020) -
Phosphorylation by Cdk1 induces Plk1-mediated vimentin phosphorylation during mitosis
por: Yamaguchi, Tomoya, et al.
Publicado: (2005)